Compare Redwire Corporation (RDW) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Redwire Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Redwire Corporation trades at $9.93 (market cap $2.56B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: Redwire Corporation and Recursion Pharmaceuticals Inc are close in size by market cap, and Recursion Pharmaceuticals Inc is more actively traded (40,478,768 versus 14,037,053). Which is the better fit depends on your goals — on Pluang, investors hold Redwire Corporation for 18 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| RDW | RXRX | |
|---|---|---|
Market Cap | $2.56B | $2.31B |
Volume | 14,037,053 | 40,478,768 |
Sector | Industrials | Health |
52-Week High | $25.90 | $6.79 |
52-Week Low | $5.06 | $2.84 |
Typical Hold Time | 18 Days | 22 Days |
Enterprise Value | $2.09B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Redwire Corporation (RDW) trades at $10.24, down 3.58% with bearish technical signals despite 80% analyst buy ratings. The company shows strong revenue growth (89.6% YoY in Q2 2026) but faces profitability challenges with negative net margins (-57.26%) and consecutive earnings misses. Recent Space Force contract wins and partnerships highlight growth potential in the expanding space infrastructure market, though cash flow remains negative from operations.
The stock presents a high-risk growth opportunity with significant upside to the $14.88 consensus target if execution improves, but persistent losses and dependence on SpaceX's Starship timeline create substantial volatility. Investors must weigh strong institutional support against fundamental weaknesses in a speculative sector.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
